Alert icon
We're changing our privacy policy. This stuff matters.  Learn more  Dismiss

Serious Infection in Lupus Patients Treated with Rituxan

Loading...

Sign in or sign up now!
Alert icon
Upgrade to the latest Flash Player for improved playback performance. Upgrade now or more info.
3,709
Loading...
Alert icon
Sign in or sign up now!
Alert icon

Uploaded by on Jun 5, 2008

FDA is alerting health care professionals and patients about new reports of a serious viral infection in patients with systemic lupus erythematosus who were treated with Rituxan (rituximab). Rituxan is an immunosuppressant drug that is approved to treat certain patients with rheumatoid arthritis and non-Hodgkin's lymphoma. It is not approved to treat lupus.

The FDA advisory says that two patients with lupus died after being treated with Rituxan. These patients developed a life-threatening viral infection of the brain called progressive multifocal leuko-encephalopathy (PML). PML is caused by reactivation of the JC virus. There are no known treatments for PML and it is usually fatal. PML has also occurred in patients with lymphoid malignancies who have been treated with Rituxan.

FDA is working with Genentech, the manufacturer of Rituxan, to get more information about the occurrence of PML in patients treated with the drug and to strengthen the warnings for this product. Here is what FDA's advisory recommends:

• Physicians who are thinking about treating a patient with Rituxan for any condition should tell their patients about the chance of PML because there is no effective treatment for the disease.

• Healthcare professionals should be on the alert for the development of PML in patients being treated with the drug.

• Patients on Rituxan should contact their physicians if they experience any new neurological signs or symptoms such as confusion, dizziness, loss of balance, difficulty talking or walking and vision problems. These could be warning signs of PML, but they could also be associated with the underlying disease for which the drug was prescribed.

• Finally, healthcare providers and patients should report suspected PML or other serious adverse events following Rituxan therapy through FDA's MedWatch program.

Category:

News & Politics

Tags:

License:

Standard YouTube License

  • likes, 1 dislikes

Link to this comment:

Share to:
see all

All Comments (4)

Sign In or Sign Up now to post a comment!
  • Health care costs wouldn't be so high if there were no lawyers (aka sub humans) running around making frivolous lawsuits against pharma companies.

  • Im scraed im getting this in 3 weeks:C Im 18 im too young to die :C

  • I was treated with Rituxan once for Lupus. I could barely stay awake for three days. I wonder if my confusion and blurred vision is caused by the Rituxan.

Loading...
Alert icon
0 / 00Unsaved Playlist Return to active list
    1. Your queue is empty. Add videos to your queue using this button:
      or sign in to load a different list.
    Loading...Loading...Saving...
    • Clear all videos from this list
    • Learn more